Brainstorm Cell Therapeutics Inc. - Common Stock (BCLI)
1.2702
-0.0898 (-6.60%)
NASDAQ · Last Trade: May 20th, 3:04 PM EDT
Detailed Quote
Previous Close
1.360
Open
1.280
Bid
1.270
Ask
1.280
Day's Range
1.120 - 1.340
52 Week Range
0.7233 - 10.05
Volume
2,223,694
Market Cap
10.05M
PE Ratio (TTM)
-0.8412
EPS (TTM)
-1.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,932,862
Chart
About Brainstorm Cell Therapeutics Inc. - Common Stock (BCLI)
Brainstorm Cell Therapeutics is a biotechnology company focused on developing innovative therapies aimed at treating neurodegenerative diseases and neurological conditions through the harnessing of stem cell technology. The company is particularly known for its research and development of treatments using its proprietary approach to generating cells that can potentially repair or regenerate damaged tissues in the central nervous system. By leveraging its expertise in cellular therapy, Brainstorm Cell aims to provide new hope for patients suffering from debilitating disorders. Through ongoing clinical trials and research initiatives, the company is committed to advancing its scientific discoveries into effective treatment options. Read More
BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.
